

【Therapeutic category】 Other biological preparations

【Non-proprietary name】 Tocilizumab(genetical recombination)

Tocilizumab(genetical recombination) [tocilizumab biosimilar 1]

Tocilizumab(genetical recombination) [tocilizumab biosimilar 2]

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
11.ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11.ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Drug-induced hypersensitivity syndrome</u> <u>Initial symptoms of rash and pyrexia, followed by serious delayed symptoms of hypersensitivity accompanied by hepatic impairment, swollen lymph nodes, increased white blood cell, eosinophilia, and appearance of atypical lymphocytes may occur. Symptoms are often accompanied by virus reactivation, such as human herpes virus type 6 (HHV-6). Caution is required for recurrence or prolongation of rash, pyrexia, hepatic impairment, etc. that may occur even after discontinuation of administration.</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.